BioAge Labs, Inc. (BIOA)
Levi & Korsinsky Investigates Possible Securities Fraud Violations by BioAge Labs, Inc. (BIOA)
NEW YORK, NY / ACCESSWIRE / January 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of BioAge Labs, Inc. ("BioAge Labs, Inc.") (NASDAQ:BIOA) concerning possible violations of federal securities laws. After the company discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns over elevated liver transaminase levels in participants.
BioAge Labs Inc Is Being Investigated For Securities Law Violations And The Schall Law Firm Encourages Affected Shareholders To Reach Out
LOS ANGELES, CA / ACCESSWIRE / January 4, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BioAge Labs, Inc. ("BioAge" or "the Company") (NASDAQ:BIOA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
BioAge Labs, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by BioAge Labs, Inc. (BIOA)
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of BioAge Labs, Inc. ("BioAge Labs, Inc.") (NASDAQ:BIOA) concerning possible violations of federal securities laws. After the company discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns over elevated liver transaminase levels in participants.
BIOA INVESTIGATION: A Class Action Investigation has been Started against BioAge Labs, Inc. - Contact BFA Law
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into BioAge Labs, Inc. (NASDAQ:BIOA) for potential violations of the federal securities laws. If you invested in BioAge, you are encouraged to obtain additional information by visiting Click Here
BIOA ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your BioAge Labs, Inc. investment
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of BioAge Labs, Inc. ("BioAge Labs, Inc.") (NASDAQ:BIOA) concerning possible violations of federal securities laws. After the company discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns over elevated liver transaminase levels in participants.
BIOA STOCK ALERT: Levi & Korsinsky Notifies BioAge Labs, Inc. Investors of an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of BioAge Labs, Inc. ("BioAge Labs, Inc.") (NASDAQ:BIOA) concerning possible violations of federal securities laws. After the company discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns over elevated liver transaminase levels in participants.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioAge Labs, Inc. - BIOA
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of BioAge Labs, Inc. ("BioAge" or the "Company") (NASDAQ:BIOA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Shareholders that lost money on BioAge Labs, Inc. (BIOA) should contact Levi & Korsinsky about Securities Fraud Investigation - BIOA
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of BioAge Labs, Inc. ("BioAge Labs, Inc.") (NASDAQ:BIOA) concerning possible violations of federal securities laws. After the company discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns over elevated liver transaminase levels in participants.
Investors With Losses Are Invited To Join The Schall Law Firm In An Inquiry Into BioAge Labs Inc For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / January 3, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BioAge Labs, Inc. ("BioAge" or "the Company") (NASDAQ:BIOA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
BIOA STOCK ALERT: Levi & Korsinsky Notifies BioAge Labs, Inc. Investors of an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of BioAge Labs, Inc. ("BioAge Labs, Inc.") (NASDAQ:BIOA) concerning possible violations of federal securities laws. After the company discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns over elevated liver transaminase levels in participants.
Did BioAge Labs, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - BIOA
NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of BioAge Labs, Inc. ("BioAge Labs, Inc.") (NASDAQ:BIOA) concerning possible violations of federal securities laws. After the company discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns over elevated liver transaminase levels in participants.
BIOA STOCK NEWS: Lose Money when BioAge Labs Stock Dropped 76%? Contact BFA Law about Your Rights
NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into BioAge Labs, Inc. (NASDAQ:BIOA) for potential violations of the federal securities laws. If you invested in BioAge, you are encouraged to obtain additional information by visiting Click Here
